Welcome to our dedicated page for Soligenix SEC filings (Ticker: SNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Soligenix, Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical issuer developing rare-disease therapeutics and public health vaccine candidates. Form 8-K reports disclose clinical and regulatory events for HyBryte in cutaneous T-cell lymphoma and SGX945 (dusquetide) in Behçet's Disease, including trial-result announcements, orphan drug designations and corporate progress updates.
Registration statements and material-event filings describe Soligenix's capital structure, including common stock, warrants, preferred stock and at-the-market or public offering activity. The filing record also covers Nasdaq continued-listing compliance, material agreements, governance matters, operating and financial results, risk factors and shareholder voting matters tied to its drug-development pipeline.
Soligenix, Inc. files a Prospectus Supplement No. 1 dated May 8, 2025, registering 408,640 shares of common stock underlying previously issued common warrants. The supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026 and updates the Final Prospectus. As of May 1, 2026, shares outstanding were 14,824,174. The Form 10-Q shows cash of $6,029,430, a net loss of $(2,824,965) for the quarter, and management discloses that substantial doubt exists about the Company’s ability to continue as a going concern; management expects cash runway into 2027 but notes additional financing is required. The supplement also references an At-Market Issuance Sales Agreement providing up to $3.5M aggregate potential gross proceeds, with approximately $0.8M capacity remaining as of May 1, 2026.
Soligenix, Inc. files a Prospectus Supplement and Form 10-Q and registers 4,253 shares of common stock underlying previously issued common warrants.
The company reported $6,029,430 in cash and cash equivalents and a net loss of $2,824,965 for the three months ended March 31, 2026. As of May 1, 2026, 14,824,174 shares were outstanding. Management states cash runway to support operations into 2027 but also notes substantial doubt about the ability to continue as a going concern and plans to seek additional financing, including sales under an ATM facility with remaining capacity of approximately $0.8 million. The Data Monitoring Committee recommended halting the FLASH2 Phase 3 trial for futility and the company is analyzing the data to determine causes.
Soligenix, Inc. supplements its March 31, 2026 prospectus to register for resale up to 1,054,688 shares of common stock issuable upon exercise of previously issued warrants by the selling stockholders. The supplement includes the Company’s Form 10-Q for the quarter ended March 31, 2026.
Key reported figures: cash and cash equivalents of $6,029,430, a net loss of $(2,824,965) for Q1 2026, and 14,824,174 shares outstanding as of May 1, 2026. Management states cash runway to support operations into 2027 but also discloses that these factors raise substantial doubt about the Company’s ability to continue as a going concern. The prospectus supplement is a resale registration for selling holders; proceeds treatment is described in the Final Prospectus.
Operational update: the Data Monitoring Committee recommended halting the FLASH2 Phase 3 HyBryte™ trial for futility; the Company is analyzing the data.
Soligenix, Inc. filed a Prospectus Supplement registering 5,330,560 shares of common stock underlying previously issued common warrants.
The supplement, dated May 8, 2026, supplements the prospectus dated March 31, 2026 and includes the Form 10-Q for the quarter ended March 31, 2026. The filing also discloses cash and cash equivalents of $6,029,430, a net loss of $2,824,965 for the quarter, and management's statement that current resources and plans provide cash runway into 2027. As of May 1, 2026, 14,824,174 shares of common stock were outstanding.
Soligenix, Inc. reported a net loss of $2.8 million for the three months ended March 31, 2026, similar to the prior-year period, with no revenue and operating expenses of $2.9 million driven by research and development and general and administrative costs.
Cash and cash equivalents were $6.0 million and working capital was $2.9 million as of March 31, 2026. Management believes this cash can support operations into 2027, but explicitly states there is substantial doubt about the company’s ability to continue as a going concern because it does not have sufficient cash to fund operations for at least 12 months from the filing date.
The company’s lead CTCL program, HyBryte, suffered a major setback when the Data Monitoring Committee recommended the confirmatory Phase 3 FLASH2 trial halt for futility after an interim efficacy analysis in April 2026, and the company is analyzing the data. Soligenix continues to advance other rare disease candidates, including SGX302 for psoriasis and SGX945 for Behçet’s Disease, and maintains access to equity financing through a Rodman at-the-market facility with approximately $0.8 million of potential gross proceeds remaining as of May 1, 2026.
Soligenix, Inc. announced that an interim efficacy analysis by the Data Monitoring Committee for its pivotal Phase 3 FLASH2 trial of HyBryte™ in cutaneous T‑cell lymphoma recommended the study halt for futility. The company expressed disappointment and plans to analyze the data to understand why efficacy did not meet expectations and whether specific patient subsets might still benefit.
With approximately $5.9 million of cash, Soligenix says it will evaluate strategic options, including potential mergers or acquisitions and advancing dusquetide for Behçet’s Disease. The company cautions that, following discontinuation of FLASH2, its ability to continue as a going concern depends on successfully developing remaining pipeline assets and securing sufficient capital; failure to do so could require significant downsizing, asset sales, or liquidation.
Soligenix, Inc. files a Post-Effective Amendment to its Form S-1 to update the prospectus and continue the registration of 5,330,560 Warrant Shares of common stock underlying previously issued warrants. The Offering Warrants exercise at $1.35 per share for five years. The prospectus states 10,306,079 shares outstanding prior to the offering and 15,636,639 shares if all Offering Warrants are exercised. The company discloses cash of $7.9 million as of December 31, 2025 and $5.9 million as of March 24, 2026, and notes a going concern with runway into the fourth quarter of 2026 absent additional financing.
Soligenix, Inc. amends its Form S-1 to register up to 1,054,688 shares of common stock issuable upon exercise of July 2024 warrants for resale by selling stockholders. The company will not receive proceeds from these resales.
As of March 24, 2026, there were 10,306,079 shares outstanding and the last reported Nasdaq sale price was $1.17. The filing incorporates the company’s Form 10-K for the year ended December 31, 2025 and discloses limited cash on hand, a going concern qualification, and an existing at-market equity sales agreement with potential remaining capacity.